Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
PROCEPT BioRobotics's operating assets for the quarter that ended in Mar. 2026 was $241.4 Mil. PROCEPT BioRobotics's operating liabilities for the quarter that ended in Mar. 2026 was $61.4 Mil. PROCEPT BioRobotics's Total Assets for the quarter that ended in Dec. 2025 was $508.1 Mil. Therefore, PROCEPT BioRobotics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.35.
PROCEPT BioRobotics Scaled Net Operating Assets Related Terms
PROCEPT BioRobotics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics Scaled Net Operating Assets Chart
PRCT vs ALMR, AHCO, ENOV: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.35 mean?
PROCEPT BioRobotics (PRCT) has a Scaled Net Operating Assets of 0.35 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Scaled Net Operating Assets too high?
PROCEPT BioRobotics' current Scaled Net Operating Assets is 0.35. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Scaled Net Operating Assets compare to ALMR and AHCO?
PROCEPT BioRobotics' Scaled Net Operating Assets of 0.35 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Scaled Net Operating Assets is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $91.98, compared to a current price of $20.85 — trading 77.3% below its estimated fair value. The current Scaled Net Operating Assets is 0.35. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Scaled Net Operating Assets is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Scaled Net Operating Assets: 0.35
GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
